Harvard Business Review

JUNE 1, 2012

She certainly wouldn't disapprove of an employee seeking prescription help to become more productive. Or should management pretend those options don't exist? Most managers would believe they're doing a good thing if they encouraged a hard-of-hearing employee to explore a hearing aid or a visually-impaired colleague to consider glasses.

Health Care 12

Health Care Ethics Pharmaceuticals Globalization 12

Harvard Business Review

MAY 29, 2013

SAP, the German software giant, announced that it hopes to hire hundreds of autistics as talented programmers and product testers. SAP''s Bangalore office saw its productivity increase after deploying autistic hires. Talk about turning a bug into a feature. Does this describe any of your better colleagues, clients and/or employees?

Competitive Advantage 8

Competitive Advantage Ethics Human Resources Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. Negative results are usually not published at all.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

JULY 14, 2017

Pharmaceutical company Lilly has said , “Many tragic world events have shaken our employees, making it difficult for them to bring their full selves to work. ” Managers should set the tone by encouraging people to speak up, teaching people how to have difficult conversations , and managing any disagreements on their teams.

Diversity 9

Diversity Politics Survey Incubator 9

Harvard Business Review

NOVEMBER 5, 2015

As a child I felt no particular interest in pharmaceuticals, telecommunications, computers, oil and gas, health and beauty aids, medical devices, airlines, or shipbuilding, all of which I’ve simulated or war-gamed. I didn’t ponder whether shareholder wealth should be the sole fiduciary duty of top management.

Career 8

Career Seminar Self-aware Telecommunications 8

Harvard Business Review

OCTOBER 13, 2014

By forcing organizations to clearly articulate their goals and then to rigorously judge their decisions by those metrics, experimental tests can help managers avoid costly mistakes and can open up the consideration of other possible solutions. Take the issue of productivity. Change management Human resources Operations'

Flextime 11

Flextime Call Center Human Resources CRM 11

Harvard Business Review

SEPTEMBER 15, 2014

Now more than ever , businesses are reaching beyond the boundaries of their organizations, tapping experts, customers, and, more broadly, “the crowd” to build new products, services, and other solutions. Informal leadership Managing people' But as corporate leaders join this trend, they should be mindful of the two types of networks.

Gilbert 9

Gilbert Participative Cooper Network Economy 9

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 8

Finance Banking Press Release Pharmaceuticals 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1% However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8